Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized monoclonal antibodies, the U.S. government, in coordination with Eli Lilly, will stop the distribution of bamlanivimab alone starting today, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced. Provider sites will still be able to order bamlanivimab/etesevimab, etesevimab alone to pair with existing stock of bamlanivimab on hand or REGEN COV following existing ordering and reporting procedures.

The Food and Drug Administration Friday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy. 
 

Related News Articles

Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is holding an emergency meeting this afternoon on the Johnson…
Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…